Misplaced Pages

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Long COVID Neurological and psychological symptoms Post-exertional malaise Society Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health Migration Military Notable deaths Other health issues Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Politics Diplomacy Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

V451 was a COVID-19 vaccine candidate developed by the University of Queensland and the Australian pharmaceutical company CSL Limited. The vaccine candidate used the University of Queensland's molecular clamp technology and the MF59 adjuvant.

Description

V451 is a protein subunit vaccine. As part of the vaccine's design, researchers added "a fragment of one protein found on the HIV virus" as a "ground-breaking molecular clamp technology".

Terminated trial

The development of the vaccine was cancelled on 11 December 2020 during its Phase I trial, after a number of trial participants were found to give false positive test results for HIV antibodies when they did not in fact have HIV. This was due to the HIV virus fragment used as a molecular clamp leading to "a partial antibody response" to HIV. This is an undesirable outcome as it will interfere with future HIV screening tests for affected participants.

Nine days prior to the termination, on 2 December, the first emergency use authorisation had been granted to a COVID-19 vaccine; the Pfizer–BioNTech COVID-19 vaccine in the United Kingdom. Following the termination of V451, vaccine production capacity by CSL Limited was diverted to the Oxford–AstraZeneca COVID-19 vaccine.

References

1. "UQ-CSL V451 Vaccine". www.precisionvaccinations.com. Archived from the original on 2020-12-19. Retrieved 2020-12-11.
2. Meneguzzi J (13 November 2020). "Why a COVID-19 vaccine could further imperil deep-sea sharks". National Geographic. Archived from the original on November 13, 2020.
3. Slezak, Michael (11 December 2020). "How the UQ coronavirus vaccine induced false-positive HIV test results and why scientists were prepared". ABC News.
4. Smyth J (11 December 2020). "Australia abandons local Covid vaccine over HIV test concerns". Financial Times.(subscription required)
5. "Covid: Australian vaccine abandoned over false HIV response". BBC News. 2020-12-11. Retrieved 2020-12-11.
6. "BRIEF-CSL Says Will Not Progress UQ-CSL V451 COVID-19 Vaccine Candidate To Phase 2/3 Clinical Trials". Reuters. 2020-12-10. Retrieved 2020-12-11.
7. "Australia ends local COVID vaccine trials due to HIV false positives". Deutsche Welle. 11 December 2020.
8. "UK medicines regulator gives approval for first UK COVID-19 vaccine". Medicines and Healthcare products Regulatory Agency (MHRA). 2 December 2020. Archived from the original on 2 December 2020. Retrieved 2 December 2020.
9. "COVID-19 Update". www.csl.com. Retrieved 2021-01-31.

External links

• Clinical trial number NCT04495933 for "A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults" at ClinicalTrials.gov

• Australian COVID-19 vaccines
• Clinical trials related to COVID-19
• Pharmaceutical industry in Australia
• Protein subunit vaccines